Canadian Authorities Approve Safety Assessment of β-Lactoglobulin from yRMK-66 Strain of Pichia pastoris

In 2022, the Canadian Health Department received an application to sell β-lactoglobulin produced by a novel yeast strain called yRMK-66, derived from Pichia pastoris. β-lactoglobulin is a protein found in bovine whey protein, and this variant shares the same characteristics. To ensure its safety for consumption, Canadian scientists conducted a comprehensive scientific assessment, examining the development of the genetically modified yeast strain, the production process of β-lactoglobulin, and any potential risks associated with its consumption.

Experts with knowledge in molecular biology, microbiology, toxicology, chemistry, and nutrition analyzed the data and provided a thorough evaluation of the applicant's information and proposed plans. Based on this assessment, it was determined that β-lactoglobulin produced by the yRMK-66 yeast strain does not pose a greater risk to human health compared to commercially available bovine whey protein in the Canadian market. Furthermore, the Canadian Health Department concluded that there is no nutritional difference between this yeast-derived β-lactoglobulin and the whey protein found in milk. However, it is important to note that individuals with milk allergies may experience similar allergic reactions when consuming products containing β-lactoglobulin. Therefore, all products containing β-lactoglobulin will be labeled to indicate the presence of milk allergens.

The evaluation of β-lactoglobulin produced by the yRMK-66 strain of Pichia pastoris was conducted in accordance with the new food safety assessment guidelines established by the Canadian Health Department. The methods employed in this assessment are based on scientific principles formulated through international expert consultations with organizations such as the World Health Organization, the Food and Agriculture Organization of the United Nations, and the Organization for Economic Co-operation and Development. The approach taken by Canada is currently adopted by regulatory authorities in the European Union, Australia/New Zealand, Japan, the United States, and other countries.

Canadian health authorities have granted approval for the sale and use of β-lactoglobulin derived from the yRMK-66 strain of Pichia pastoris following a rigorous safety assessment. This decision assures consumers that the yeast-derived protein does not pose a greater risk to human health compared to commercially available bovine whey protein. With appropriate labeling to indicate the presence of milk allergens, this approval opens up opportunities for the use of β-lactoglobulin in various food products within Canada. The Canadian Health Department's evaluation process adheres to internationally recognized scientific principles, ensuring the safety of novel food ingredients for consumption.